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Abstract
Robyn Ott is a third-year law student at the University of Oklahoma College of Law. She
is also the Managing Editor of the Oklahoma Journal of Law and Technology for the
2004-2005 academic year. Ms. Ott wrote this eBrief under the direction of Professor
Drew Kershen while working on the Project on Intellectual Property Rights in Living
Matter. Below, Ms. Ott discusses the legal effect of India’s Patents Act and the general
requirements for determining the patentability of living matter under the Act.
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I.

Introduction

India is a member of the Trade Related Aspects of the Intellectual Property
Systems (TRIPS) agreement, and is therefore required to meet minimum intellectual
property right standards. 1 Specifically, Article 27(1) requires TRIPS member states to
grant patents for any invention in all fields of technology. 2 However, TRIPS does allow
states to exempt certain substances and processes from patentability. 3
The Patents Act of 1970 (Patents Act) regulates India’s patent system. The
Patents Act has fulfilled all of the temporary TRIPS requirements 4 and details what is not
patentable in India. 5 This eBrief provides specific application of the Patents Act to
inventions involving living materials in India, including plants, animals, microorganisms
and other biological material, by outlining the inventions explicitly patentable under the
1

Patents, INDIAIP.COM, at http://www.indiaip.com/patents_article.htm (last visited Mar. 19, 2004).
Agreement on Trade-Related Aspects of Intellectual Property Rights, Apr. 15, 1994, Marrakesh
Agreement Establishing the World Trade Organization, Annex 1C, Legal Instruments--Results of the
Uruguay Round vol. 31, art. 27(1), 33 I.L.M. 81 (1994) [hereinafter TRIPS] at
http://www.wto.org/english/tratop_e/trips_e/t_agm3c_e.htm#5 (last visited Mar. 6, 2004). Patents are to be
granted if they are new, involve an inventive step, and are capable of industrial application. Id.
3
Id. art. 27(3)(b).
4
Press, Information, and Culture Wing, Embassy of India, US and European Commission Commend
India’s Initiatives on Patents, INDIA NEWS ONLINE (May 1999), at
http://www.indianembassy.org/inews/May_1999/foreign.html (last visited Mar. 6, 2004).
5
Patents Act § 3 (1970) (Act 39 of 1970) (India).
2
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act and then detailing the potential obstacles for intellectual property rights in living
material and processes creating living material that are not per se patentable.
II.

Patentable Living Material in India

Article 27(3)(b) of TRIPS allows member states to deny patents for “plants and
animals, other than microorganisms, and essentially biological processes for the
production of plants or animals other than non-biological and microbiological
processes.” 6 As a result, TRIPS requires patents of microorganisms, non-biological, and
microbiological processes. 7

Further, animal and plant parts, and altered plants and

animals are not explicitly included in the exemption, which means TRIPS may also
require patenting of biological organisms. 8

Some commentators have determined,

however, that “since plants and animals are excluded, parts would also be excluded.” 9
Complying with TRIPS, the Patents Act, as amended in June 2002, gives patent
rights for new microorganisms. 10
patentable in India.

Other areas involving microorganisms are also

For example, a synergistic composition containing the

microorganism, which is either new or known, and a process using microorganisms to

6

TRIPS, supra note 2, art. 27(3)(b). States are allowed to provide for plant patents with an effective sui
generis system. Id.; see Robyn Ott, Protection of Plant Varieties and Farmers Rights Act, 2 OKLA. J.L. &
TECH. 14 (2004), available at http://www.okjolt.org/published/2004okjoltrev14.html [hereinafter Ott,
Protection].
7
Someshwar Singh, Patents on Life Forms Should Be Re-Examined, says India, SUNS SOUTH-NORTH
DEVELOPMENT MONITOR, Oct. 27, 1999, at http://www.gefoodalert.org/News/news.cfm?News_ID=1147
(last visited Mar. 19, 2004).
8
Vandana Shiva , Ecologists Should Worry About the Dunkel Draft, SUNS SOUTH-NORTH DEVELOPMENT
MONITOR, Sept. 23, 1993, at http://www.sunsonline.org/trade/areas/environm/09230193.htm (last visited
Mar. 28, 2004).
9
Singh, supra note 7. If the biological areas are excluded, the biological material can still receive a patent
if that material is also chemical, like artificial enzymes for example. The material would be patented as
chemicals. Id.
10
Patents (Amendment) Act § 4(e) (June 25, 2002) (No. 28 of 2002) (India) [hereinafter Patents
(Amendment) Act].
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produce a substance can both be patented. 11 Also, the process of biosynthesis of a new
microorganism is patentable. 12 Microorganisms that are lyophilized as an end product are
patentable. 13
The Calcutta High Court in India has addressed the issue of whether a process
involving microorganisms that are living as an end product can be patented in a 2002
case. 14 It should be noted here that the definition of invention, which was litigated in the
case, has been amended since this case was decided. 15 Prior to the case, the applicant had
requested a patent for the process of creating a vaccine to protect poultry from infectious
bursitis. 16 The Controller of Patents determined the process was not an invention because
the end product produced by the process contained a living organism, and thus was not
patentable. 17

The applicant appealed the Controller’s decision to the Calcutta High

Court. The Controller claimed a patent is given only for a process that results either in an

11

N.R. Subbaram, Protection of Biotech Inventions, HINDU, Dec. 29, 2003, at
http://www.hindu.com/biz/2003/12/29/stories/2003122900321600.htm (last visited Mar. 19, 2004). These
processes are patentable subject to the requirements for patentability under the patents act, which
specifically requires a new process that involves an inventive step; see Robyn Ott, Patentability of Plants,
Animals and Microorganisms in India, 2 OKLA. J.L. & TECH. 16 (2004), available at
http://www.okjolt.org/published/2004okjoltrev16.html [hereinafter Ott, Patentability].
12
Subbaram, supra note 11.
13
Dimminaco A. G. v. Controller of Patents Designs and Ors., AID No. 1 of 2001, Jan. 15, 2002.
Lyophilization (or freeze drying) is “the process of removing water from a frozen biomaterial via
application of a vacuum.” KIMBALL R. NILL, GLOSSARY OF BIOTECHNOLOGY TERMS 148 (2d ed. 1998).
14
Id. This case, however, held a living end product was an invention based on the old Patents Act
definition of invention. Id.
15
The definition of invention was amended six months after this case was decided; see Ott, Patentability,
supra note 11.
16
Dimminaco, AID No. 1 of 2001.
17
The Controller of Patents argued that the process could not be considered a manufacture or substance,
under the old definition, meaning the process could not be an invention. Id. Under the old definition, an
invention was “any new and useful (i) art, process, method or manner of manufacture; (ii) machine,
apparatus or other article; [or] (iii) substance produce by manufacture, and includes any new and useful
improvement of any of them, and an alleged invention.” Under the new definition, these specific
classifications are not required, see Patents (Amendment) Act § 3(f).
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article, substance, or manufacture and a vaccine with a living organism is not an article, 18
substance, 19 or manufacture.

The court used the normal dictionary meaning of

manufacture, because it was not defined in the Patents Act, and determined manufacture
is where “the material in question after going through the process of manufacture has
under-gone any change by the inventive process and it becomes a material which is
different from the starting material.”

The court determined this meaning does not

exclude the process of preparing a product that contains a living substance from
patentability. The court found that no statute precluded a living end product from the
definition of manufacture. Also, the court decided that “since the claim process for
patent leads to a vendible product, 20 it is certainly a substance after going through the
process of manufacture.” 21 The court ultimately concluded that “a new and useful art or
process is an invention,” and because the process is new and useful, it “is apparently
patentable under section 5 22 read with section 2(j)(i)” 23 of the Patents Act. The court
determined that “where the end product is a new article, the process leading to its
manufacture is an invention.” 24 Although the definition of invention has been amended,
this change may actually enhance the court’s invention argument, because now the
elements of manufacture, article, or substance are no longer required. Rather, the new

18

The Controller claimed the dictionary meaning of article is a “material thing, item, a thing of a particular
class or kind as distinguished from a thing of any class of kind.” The Controller said the definition does not
cover living things. Dimminaco, AID No. 1 of 2001.
19
The Controller showed “substance” is not defined in the Patents Act, and thus the dictionary meaning of
“species of matter of a definite chemical composition or a solid or real thing as opposed to appearance or
shadow” or “the muscular tissue or fleshy art of any animal body” also did not describe a living thing. Id.
20
The court details the requirements of a vendible product, see discussion of vendible products infra.
21
Dimminaco, AID No. 1 of 2001.
22
Section 5 says a product intended for use, or capable of being used, as food or medicine or drug, or which
is created by a chemical process is not patented.
23
Section 2(j)(i) is the definition of invention under the old Patents Act.
24
Dimminaco, AID No. 1 of 2001.
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definition merely calls for a new, non-obvious and useful product or process. 25 As noted
above, the court determined the vaccine was new and useful and made no discussion
about the end product containing living material in reaching this conclusion. However,
other changes to the act may change the case’s outcome. For example, section 3(j) was
added to the Patents Act after this case and now excludes essentially biological processes
for production or propagation of plants and animals from the definition of invention. In
that case, the court cautioned that claims for patentability should “be considered by the
controller on the principle of section 3” of the Patents Act.
In secondary arguments, the Controller of Patents also claimed the process was
not patentable because it was a substance prepared by a process that is capable of being
used as food or drug.

This second argument was quickly disregarded because the

applicant had applied for a patent on the process for the preparation of the vaccine instead
of applying for a patent on the product.

26

The case also found that administrative

policies, such as those of the Patents Office, cannot override statutory provisions like the
Patents Act. 27 As a result, this decision may “caution the Patent Office from further use
of obscure administrative policies to override statutory provisions.” 28 Although the court
found the end product containing a living organism was patentable, the court did explain

25

See discussion infra.
Section 5 of the Patents Act prohibits the product from patentability where the product is intended for use
or capable of being used as, among other things, medicine or drug. The applicant, however, was only
patenting the process, which is allowed under the Patents Act. This portion of Section 5 is from the
original Patents Act and was not changed in the subsequent amendments, see Ott, Patentability, supra note
11.
27
Dimminaco, AID No. 1 of 2001.
28
Manufacture Applies to Living Organism, BUSINESS LINE, at
http://www.patentmatics.com/news2002/news25.htm (last visited Mar. 28, 2004) (citing Samarash
Chakraborty, attorney for the applicant).
26
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that a claim that a product or process is patentable, because it fits the definition of
invention, must be decided on the facts of each case. 29
In addition to microorganisms, India has provided guidance for the patentability
of other living materials. However, the Patents Act differs significantly from TRIPS by
explicitly denying patent rights for any part of plants or animals including seeds,
varieties, and species. 30

Moreover, the Patents Act has elected to place chemical

processes, including biochemical, biotechnological and microbiological processes in a
specific section of the act that only grants patent rights to the chemical process but not the
substance. 31 For example, the process of creating a biochemical substance is patentable,
but the substance itself cannot be patented. TRIPS has given India, and other developing
countries until January 1, 2005 to achieve full compliance with TRIPS, 32 which includes
providing product patents for life forms of non-biological, microbiological 33 and
biological processes. 34
India has also placed substances intended for or capable of being used as food or
medicine in the section that provides only for process patents. 35 As a result, substances
for use in diagnostic kits and drug delivery systems that were developed by the use of

29

Dimminaco, AID No. 1 of 2001.
Patents (Amendment) Act § 4(e).
31
Patents Act § 5(1)(b).
32
Comments to the Patents (Amendment) Act indicate that “it is unlikely that the Act will be amended
before [January 2005] to allow product patent[s] . . . .” Ministry of Law, Justice and Company Affairs,
Extraordinary, (No. 42, June 25, 2002) at
http://www.dpahuja.com/newpatentsact/Patent%20Act%202002%20and%20Comments.pdf (last visited
Mar. 28, 2004).
33
TRIPS, supra note 2, art. 65(4), see Ott, Patentability, supra note 11.
34
Shiva, supra note 8. If TRIPS does not allow for plant and animal parts, and altered plants and animals,
then these biological process exclusions must be removed from the Patents Act in order for India to become
TRIPS compliant, meaning the Patents Act will be required to allow patents for biological organisms.
35
Patents Act § 5(1)(a).
30
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plasmids and DNA, are not patentable in India. 36 Only the process for preparing the
substances is patentable.
Both TRIPS and the Patents Act exclude plants, animals, and essentially
biological processes for the production of plants and animals from patentability. 37
Although plants do not have to be patented, TRIPS does require member states either to
provide patent rights or an effective sui generis system to protect plant varieties. 38 India
has elected to provide a sui generis system through the Protection of Plant Varieties and
Farmers Rights Act. 39
III.

Requirements for Patentability

Although TRIPS and the Patents Act have provided explicit areas of patentability,
some areas are still uncertain, particularly the patentability of living materials. 40 TRIPS
has not given guidance for patentability of life forms, except those mentioned above.
Instead, TRIPS has allowed member states to determine the patent rights for these
remaining life forms. 41
In India, living materials are patentable if they satisfy the Patents Act
requirements. 42 India’s patent law requires the material or process to meet the definition

36

Subbaram, supra note 11. India has been given until January 1, 2005 to provide product patents for these
substances. If India does not change its law, India will no longer be TRIPS compliant. Carole De Gaulle,
Intellectual Property and Patent in India, NEWS TIME, Oct. 2000, at
http://www.foxmandal.com/publication/oct2000/oct2kca.html (last visited Mar. 28, 2004).
37
See TRIPS, supra note 2, art. 27(3)(b); Patents (Amendment) Act § 4(e).
38
TRIPS, supra note 2, art. 27(3)(b); see Ott, Protection, supra note 6.
39
B.J. Krishnan, Move to Join UPOV, HINDU BUSINESS LINE, Oct. 2, 2002, at
http://www.mindfully.org/WTO/UPOV-Farmers-Rights10oct02.htm (last visited Mar. 28, 2004); see Ott,
Protection, supra note 6.
40
Subbaram, supra note 11.
41
Patents, supra note 1.
42
Subbaram, supra note 11.
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of invention, which includes a distinction from a discovery. Further, the invention must
be sufficiently disclosed, meet the vendibility test, and be within the public interest. 43
In the Patents Act, invention is defined as a new product or process involving an
inventive step and capable of industrial application. 44 Although the terms “inventive
step” and “capable of industrial application” are individually defined in the Patents Act,
the meanings are taken from Article 27(1) of TRIPS, which defines the terms as nonobvious and useful. 45
Under the act, a patent must be an invention, and not a discovery, meaning it must
meet the required criteria of new, non-obvious, useful, and repeatable. The Patents Act
excludes the discovery of “any living thing or non-living substance occurring in nature,”
from patentability. 46 To meet this initial criteria, the product or process must be “isolated
from nature by the application of human intellect” in order to be an invention, and not
discovery. 47 For an invention to be considered new, it must not have been “disclosed to
the public either in writing or orally, by use or otherwise” in India or elsewhere before
the date of filing. 48

To meet the non-obviousness requirement, the invention, as

described in the Patent Act, must involve anything beyond the ability of someone skilled
in the art. 49

In order for the invention to be useful, it must be an invention that

43

See Ott, Patentability, supra note 11.
Patents (Amendment) Act § 4(e). For a discussion on the old and new definition of invention, see Ott,
Patentability, supra note 11.
45
Section 2(ja) of the Patents Act defines inventive step as “a feature that makes the invention not obvious
to a person skilled in the art.” Capable of industrial application is defined in section 2(ac) as an invention
that “is capable of being made or used in an industry.”
46
Patents (Amendment) Act § 4(b).
47
Subbaram, supra note 11.
48
Id.; see Patents Act § 13.
49
SME Network, What Is a Patent?, at http://www.smenetwork.net/patents/Patentsbasic.htm (last visited
Mar. 19, 2004); see Patents (Amendment) Act § 3(f).
44
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functions. 50 Under the old definition of invention, the Patents Office manual said an
element of commercial or pecuniary success has no relation to usefulness for purposes of
patentability. 51 The manual also said usefulness merely depends on whether the result as
promised by the applicant in the application actually occurs. 52 Finally, the Patents Act
also requires an invention to be repeatable, thus enabling others to repeat the invention. 53
In order for an applicant to patent living material, the applicant must also prove
sufficient disclosure. 54 The Patents Act requires that every patent application “fully and
particularly describe the invention and its operation or use and the method by which it is
performed,” including a “title sufficiently indicating the subject-matter to which the
invention relates.” 55 The application must also define the scope of the invention. All
these claims must be “as clear and concise as the nature of the subject will admit.” 56 The
sufficient disclosure requirement is mandatory, and is difficult when describing living
materials. 57 The requirement can be satisfied, however, by depositing a sample of the
living material with the International Depository Authority if the material is not available
to the public. 58 The applicant must also provide the Authority with all the available
characteristics of the biological material required for it to be correctly identified.59 Also,
the applicant must disclose the source and geographical origin of the biological

50

Patents (Amendment) Act § 3(f). This requirement is intented to avoid patenting perpetual motion
machines. Id.
51
PATENT OFFICE, INDIA, MANUAL OF PATENT PRACTICE & PROCEDURE 1.3.6 (July 2001) at
http://www.patentoffice.nic.in/ipr/patent/manual.htm (last visited Mar. 6, 2004).
52
Id.
53
Subbaram, supra note 11.
54
Patents Act § 10.
55
Id.
56
Patent Office, supra note 51, at 3.5.0; see also Patents Act § 10(5).
57
Subbaram, supra note 11.
58
Patents Act § 10(a)(4)(d)(ii)(A); see also Subbaram, supra note 11.
59
Patents Act § 10(a)(4)(d)(ii)(B),
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material. 60 If the application fails to disclose or inaccurately describes the source or
geographical origin of the biological material used for the invention, the patent may be
revoked by the High Court. 61 Once the deposits are made, the Authority provides an
accession number, which is considered as an equivalent description of the living
material. 62 After going through this process, the invention is deemed to have satisfied the
sufficient disclosure requirement. 63
The depository system was implemented to “provide a mechanism to verify
compliance with national laws and contracts concerning access to genetic resources and
benefit sharing.” 64 The regulations India has followed in adopting the depository system,
though, are not pursuant to TRIPS requirements. As noted above, TRIPS provides
minimum requirements for member states, and TRIPS has not required a depository
system for providing information on the geographic origin of genetic resources. Rather,
India has implemented the depository system to meet the provisions of the Convention on
Biological Diversity (CBD), which India adopted in 1992. 65 CBD has the purpose of
conserving biological diversity, providing for “sustainable use” of the elements of
biological diversity, and allowing for the “fair and equitable sharing of benefits” arising
from using genetic resources and appropriate transfers of relevant technology. 66 Relating
to the depository system, CBD requires parties to “respect, preserve and maintain” the

60

Id. § 10(a)(4)(d)(ii)(D). TRIPS does not require disclosure of the source of origin of the biological
material used in the invention. Patents, supra note 1.
61
Patents (Amendment) Act § 31; see S.K.Verma, Access to Plant Genetic Resources and Intellectual
Property Rights: The Case of India, CASRIP NEWSLETTER, Spring/Summer 2001, at
http://www.law.washington.edu/casrip/newsletter/newsv8i2Verma.pdf (last visited Mar. 19, 2004).
62
Subbaram, supra note 11.
63
Id.
64
Verma, supra note 61.
65
Id.
66
Patents, supra note 1.
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traditional knowledge, innovations, and practices of indigenous people and local
communities “relevant for the conservation and sustainable use of biological diversity.” 67
TRIPS, in contrast, does not require protection of traditional knowledge. 68
TRIPS and CBD both address the protection of and access to biological and
genetic resources, but the two agreements differ on the traditional knowledge
requirements. 69 However, some say the two agreements also have conflicting provisions
for technology holders and holders of genetic resources. 70 The United States disagrees,
claiming the US has not been provided with proof that “a single inconsistency between
the two agreements” exists." 71 The World Trade Organization and World Intellectual
Property Organization have addressed concerns of inconsistency and have instructed
TRIPS to “examine, inter alia, the relationship between the TRIPS Agreement and the
CBD, the protection of traditional knowledge and folklore, and other relevant new
developments raised by members . . . .” 72
In addition to the requirements outlined above, patent applications must also pass
a vendibility test to determine if the living matter should be patented. A vendible product
is something that “can be passed on from one man to another upon the transactions of

67

Convention on Biological Diversity § 8(j), 31 I.LM. 818 (1992).
Genetic Resources, Traditional Knowledge and Intellectual Property Rights, Issue brief for the World
Summit on Sustainable Development by the Center for International Environmental Law, (2002), at
http://www.ciel.org/Publications/iprights.pdf (last visited Mar. 28, 2004).
69
Verma, supra note 61.
70
Id.
71
Singh, supra note 7. The United States of America, in a paper submitted to the TRIPS Council, says “[i]t
is time, therefore, to lay to rest the allegation that the obligations of the two agreements are inconsistent and
concentrate on addressing any specific concerns that [TRIPS] members that are also members states of the
CBD might have about the manner in which they might implement particular obligations of either
agreement so that they avoid any question of conflict with obligations under the other agreement." Id.
72
Genetic Resources, supra note 68.
68
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purchase and sale.” 73 To satisfy the test, an invention must result in the production of a
vendible item, improve or restore former conditions of a vendible item, or preserve and
prevent a vendible item from being produced. 74 This test may not pose a high threat to
living organisms, as one Indian court has held that the process for creating a vaccine
leads to a vendible product even if the end product contains live material. 75
A final requirement of importance when seeking patents for living materials in
India is satisfying the public interest requirement. The Patents Act, as allowed under
TRIPS, 76 excludes inventions from patentability if their primary or intended use or
commercial exploitation is contrary to public order, morality, or causes serious prejudice
to the environment, health, or human, animal or plant life. 77 At least one commentator
has questioned whether living materials are patentable under this section due to their
environmental impact. 78
IV.

Conclusion

Although the Patents Act is not clear on every area involving patentability of
living material, the Act has given guidelines for what is and is not allowed to be patented.
Through these guidelines, the Patents Act has provided a general framework that allows
“ample scope” for protecting areas involving living materials. 79

73

Dimminaco A. G. v. Controller of Patents Designs and Ors., AID No. 1 of 2001, Jan. 15, 2002.
Id.
75
Id.
76
Article 27(2) of TRIPS allows members to “exclude from patentability inventions, the prevention within
their territory of the commercial exploitation of which is necessary to protect ordre public or morality,
including to protect human, animal or plant life or health or to avoid serious prejudice to the environment,
provided that such exclusion is not made merely because the exploitation is prohibited by their law.”
77
See Patents (Amendment) Act § 4(a); TRIPS, supra note 2, art. 27(2).
78
Verma, supra note 61.
79
Subbaram, supra note 11.
74
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